(1) Policy: The pharmaceutical and health industry has risen to a national strategic height.

"Made in China 2025" clearly proposes to focus on ten key areas such as biomedicine and high-performance medical devices.

The "Healthy China 2030" puts forward the strategic goal of reaching 16 trillion yuan in China's health service industry by 2030.

The "14th Five-Year Plan" for the Development of the pharmaceutical Industry proposed to focus on supporting about 10 cities to build pharmaceutical industry innovation highlands.

The 14th Five-Year Plan for Bioeconomy Development proposes to support the development of bioeconomy pilot zones in the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Twin City Economic Circle.

China's biomedicine industry is experiencing a nirvana from made in China to created in China, from imitation to innovation.

China's biomedicine industry is experiencing a nirvana from made in China to created in China, from imitation to innovation.

(2) Spatial end: The distribution trend of China's five major biomedical industry clusters is prominent.

At present, China has initially formed a bio-pharmaceutical industrial cluster with the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, the Chengdu-Chongqing economic Circle, and the central region as the core.

Among them, the bio-pharmaceutical industry in the Beijing-Tianjin-Hebei region presents a spatial cluster development, forming an industrial cluster with Beijing's innovation ability as the core.

The Yangtze River Delta region has initially formed an industrial pattern with Shanghai, Suzhou and Hangzhou as innovation-driven, and Hefei, Nanjing, Taizhou, Lianyungang, Wuxi, Xuzhou and other cities making synergies.

The Guangdong-Hong Kong-Macao Greater Bay Area has initially formed a development pattern driven by Guangzhou and Shenzhen, supported by Hong Kong, Macao, Zhuhai, Foshan and Zhongshan, and supported by Dongguan, Huizhou, Jiangmen and Zhaoqing.

Chengdu-chongqing economic circle has initially formed a bio-pharmaceutical industrial cluster with Chengdu and Chongqing as the core.

(3) Scale end: The scale of China's biopharmaceutical industry continues to expand.

China's biopharmaceutical industry has a solid foundation and an increasing level of innovation. From the perspective of industrial scale, according to the data of the National Bureau of Statistics, in the first half of 2023, the main business income of industrial enterprises above designated size in China's pharmaceutical manufacturing industry was 1,249.6 billion yuan, and the total profit was 179.45 billion yuan.

From January to July 2023, the number of enterprises above designated size in the national pharmaceutical manufacturing industry reached 9,390. From the perspective of investment and financing, the number of investment and financing events in the field of biomedicine in China from January to August 2023 is 142.

From the medical device approval situation, in 2023, the State Food and Drug Administration approved the listing of 61 innovative medical devices, covering high-value consumables, medical equipment, IVD reagents, involving Medtronic, Huacke precision, United film Medical, Tencent Medical and other enterprises, and a number of products for the domestic and even the world's first products.

(4) Field end: China accelerates into the new echelon of global biomedical industry development.

China's chemical drug market accounts for the majority, and biological drugs and medical devices maintain a rapid growth trend.

In the field of chemical drugs, China's chemical drugs are currently in a critical period of "cost control and quality improvement", and industry mergers and acquisitions are accelerating.

In the field of biological drugs, China's biological drugs are in the early stage of development, with a compound annual growth rate of more than 10%.

In the field of traditional Chinese medicine, at present, China's traditional Chinese medicine market is relatively stable, with a total output value of more than 800 billion yuan, and the industrial structure has become seven proprietary Chinese medicines.

In the field of pharmaceutical outsourcing, China is currently in the first echelon of accepting global industrial transfer, and the scale of pharmaceutical outsourcing market has exceeded 150 billion yuan, and there is a large room for increment.